Rhopressa logo
MENU CLOSE

Dosing & Safety

The versatility and tolerability of Rhopressa® could give your patients the unique care they need.2,6

Improve patient adherence with a simplified dosing regimen4

  • According to one study that included free medicine, guided instruction and electronic monitoring, nearly half of patients took less than 75% of their prescribed dose.4

  • Rhopressa® offers patients a simplified dosing schedule with one drop of medication per day, taken in the evening.1

Prescribe once-daily Rhopressa® for your patients to:

  • Reduce treatment burden with once-a-day, evening dosing schedule4
  • Help improve adherence to reduce the risk of disease progression through once-daily dosing4

Administration notes1

Rhopressa® requires one drop of medication per day and should be taken in the evening.

If one dose is missed, treatment should continue with the next dose in the evening.

Twice-a-day dosing is not well tolerated and is not recommended.

If Rhopressa® is to be used concomitantly with other topical ophthalmic products, administer each drug product at least 5 minutes apart.

Store Rhopressa® in the refrigerator (36 ° to 46 °F) until opened. After opening, Rhopressa® may be kept at 36 ° to 77 °F for up to 6 weeks. If after opening the product is kept refrigerated at 36 ° to 46 °F, then the product can be used until the expiration date stamped on the bottle.

ROCKET 1, 2 and 4

Once-daily Rhopressa® exhibited a safe, tolerable performance2

Tolerability of Rhopressa® was studied in >1,400 patients with OAG or OHT during 3 different Phase 3 studies.2

In clinical studies for Rhopressa®, ocular adverse events (AEs) were mild and tolerable1,2

  • 53% of patients experienced hyperemia while taking Rhopressa®1
  • Other ocular AEs in ∼20% of patients included cornea verticillata, instillation site pain, and conjunctival hemorrhage1
  • 6% of patients discontinued therapy due to conjunctival hyperemia1

Incidence of conjunctival hyperemia in patients2

Conjunctival hyperemia was either not reported or graded as mild in approximately 9 out of 10 patients.2

M.O.S.T. (Multi-center Open-label Study)

Consider adding Rhopressa® for its versatility and tolerability

89%

of patients reported Rhopressa® was tolerated “Well” or better in survey2

73%

of physician-rated patient acceptance was good or excellent2

View Savings

Help your patients save on Rhopressa®

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

Contact Lenses: Contact lenses should be removed prior to instillation of Rhopressa® and may be inserted 15 minutes following its administration.

ADVERSE REACTIONS

The most common ocular adverse reaction observed in controlled clinical studies with Rhopressa® dosed once daily was conjunctival hyperemia, reported in 53% of patients. Six percent of patients discontinued therapy due to conjunctival hyperemia. Other common (approximately 20%) adverse reactions were: corneal verticillata, instillation site pain, and conjunctival hemorrhage. Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, and reduced visual acuity were reported in 5-10% of patients.

The corneal verticillata seen in Rhopressa®- treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most corneal verticillata resolved upon discontinuation of treatment.

Please click here for full prescribing information for Rhopressa®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATIONS AND USAGE

Rhopressa® (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Bacterial Keratitis: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

Contact Lenses: Contact lenses should be removed prior to instillation of Rhopressa® and may be inserted 15 minutes following its administration.

ADVERSE REACTIONS

The most common ocular adverse reaction observed in controlled clinical studies with Rhopressa® dosed once daily was conjunctival hyperemia, reported in 53% of patients. Six percent of patients discontinued therapy due to conjunctival hyperemia. Other common (approximately 20%) adverse reactions were: corneal verticillata, instillation site pain, and conjunctival hemorrhage. Instillation site erythema, corneal staining, blurred vision, increased lacrimation, erythema of eyelid, and reduced visual acuity were reported in 5-10% of patients.

The corneal verticillata seen in Rhopressa®- treated patients were first noted at 4 weeks of daily dosing. This reaction did not result in any apparent visual functional changes. Most corneal verticillata resolved upon discontinuation of treatment.

Please click here for full prescribing information for Rhopressa®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

INDICATIONS AND USAGE

Rhopressa® (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening.

References:

  1. Rhopressa® (netarsudil ophthalmic solution) 0.02% Prescribing Information, Aerie Pharmaceuticals, Inc., Irvine, Calif. 2019.
  2. Data on file, Aerie Pharmaceuticals, Inc.
  3. Kazemi A, McLaren J, Kopczynski C, et al. The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans. J Ocul Pharmacol Ther. 2018;34(5):380-386.
  4. Prum B Jr, Rosenberg L, Gedde S, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines. Ophthalmology. 2016;123(1):P41-P111.
  5. Serle JB, Katz LJ, McLaurin E, et al. Two Phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116-127.
  6. Khouri AS, Serle JB, Bacharach J, et al; for the ROCKET-4 Study Group. Once-daily netarsudil vs twice-daily timolol in patients with elevated intraocular pressure: the randomized phase 3 ROCKET-4 study. Am J Ophthalmol. 2019;204:97-104.
  7. Wang R, Williamson J, Kopczynski C, Serle J. Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015;24(1):51-54.
  8. Ren R, Li G, Le TD, Kopczynski C, Stamer WD, Gong H. Netarsudil increases outflow facility in human eyes through multiple mechanism. IOVS. 2016;(57)14:6197-6209.
  9. Sit A, Gupta D, Kazemi A, et al. Improvement of trabecular outflow facility by netarsudil ophthalmic solution in patients with primary open angle glaucoma or ocular hypertension. Presented at The Association for Research in Vision and Ophthalmology 2019 Annual Meeting (ARVO 2019). April 28-May 2, 2019; Vancouver, BC, Canada.
  10. Managed Market Insights & Technology, May 2020.